UTR Therapeutics, UTRxMYCN M1-14, FDA, Orphan Drug Designation, Rare Pediatric Disease, Neuroblastoma, MYCN

United States, September 30, 2026 UTR Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has...